• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Treatment effects in competing-risks analysis of prostate cancer data.

作者信息

Kay R

出版信息

Biometrics. 1986 Mar;42(1):203-11.

PMID:3521753
Abstract

Green and Byar (1980, Bulletin Cancer, Paris, 67, 477-488) have analysed some data from a randomised clinical trial comparing treatment for patients with prostate cancer in stages 3 and 4. These authors assessed the effects of treatment on survival using an exponential regression model with treatment by covariate interactions. Clinical considerations led to conclusions being drawn about the relationship between treatment and different causes of death. This paper presents a more direct approach for assessing treatment effect based on a model which recognizes the competing-risks nature of the problem. Methods for choosing the optimal treatment for particular patients, one of the aims of the Green and Byar work, are also discussed.

摘要

相似文献

1
Treatment effects in competing-risks analysis of prostate cancer data.
Biometrics. 1986 Mar;42(1):203-11.
2
The choice of treatment for cancer patients based on covariate information.基于协变量信息为癌症患者选择治疗方法。
Bull Cancer. 1980;67(4):477-90.
3
Prediction of cumulative incidence function under the proportional hazards model.比例风险模型下累积发病率函数的预测
Biometrics. 1998 Mar;54(1):219-28.
4
Estimates of clinically useful measures in competing risks survival analysis.竞争风险生存分析中临床有用指标的估计。
Stat Med. 2008 Dec 30;27(30):6407-25. doi: 10.1002/sim.3455.
5
Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies.前列腺癌的激素治疗:退伍军人管理局合作泌尿外科研究组的研究结果。
NCI Monogr. 1988(7):165-70.
6
Applying Cox regression to competing risks.将Cox回归应用于竞争风险。
Biometrics. 1995 Jun;51(2):524-32.
7
An EM-based semi-parametric mixture model approach to the regression analysis of competing-risks data.一种基于期望最大化(EM)的半参数混合模型方法用于竞争风险数据的回归分析。
Stat Med. 2003 Apr 15;22(7):1097-111. doi: 10.1002/sim.1371.
8
A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials.一种通过使用分数多项式对临床试验中治疗与连续协变量之间的相互作用进行建模的新方法。
Stat Med. 2004 Aug 30;23(16):2509-25. doi: 10.1002/sim.1815.
9
Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.特异性内皮素-A受体拮抗剂ZD4054在无痛或症状轻微的激素抵抗性前列腺癌和骨转移患者中的安全性和有效性:一项双盲、安慰剂对照、随机2期试验。
Eur Urol. 2009 May;55(5):1112-23. doi: 10.1016/j.eururo.2008.11.002. Epub 2008 Nov 29.
10
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.局限性前列腺癌的雄激素剥夺治疗与心血管疾病死亡率风险
J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24. doi: 10.1093/jnci/djm168. Epub 2007 Oct 9.

引用本文的文献

1
On estimation for accelerated failure time models with small or rare event survival data.小样本或稀有事件生存数据的加速失效时间模型估计。
BMC Med Res Methodol. 2022 Jun 11;22(1):169. doi: 10.1186/s12874-022-01638-1.
2
Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials-Application of the Estimand Framework.评估2019冠状病毒病对临床试验目标的影响及肿瘤学临床试验分析——估计量框架的应用
Stat Biopharm Res. 2020 Jul 14;12(4):427-437. doi: 10.1080/19466315.2020.1785543.
3
A causal framework for classical statistical estimands in failure-time settings with competing events.
具有竞争事件的失效时间设置中经典统计估计量的因果框架。
Stat Med. 2020 Apr 15;39(8):1199-1236. doi: 10.1002/sim.8471. Epub 2020 Jan 27.
4
Model-based estimation of measures of association for time-to-event outcomes.基于模型的事件发生时间结局关联度量估计
BMC Med Res Methodol. 2014 Aug 9;14:97. doi: 10.1186/1471-2288-14-97.
5
Survival analysis part IV: further concepts and methods in survival analysis.生存分析第四部分:生存分析中的进一步概念与方法。
Br J Cancer. 2003 Sep 1;89(5):781-6. doi: 10.1038/sj.bjc.6601117.
6
A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG Collaborative Group.丙戊酸钠与卡马西平治疗成人癫痫的多中心对照试验。成人癫痫协作研究组(EPITEG)
J Neurol Neurosurg Psychiatry. 1994 Jun;57(6):682-7. doi: 10.1136/jnnp.57.6.682.